Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

St Jude Children's Research Hospital investigates gene activation triggers

St. Jude Childrens Research Hospital : 25 June, 2007  (Company News)
A research team at St Jude Children's Research Hospital have discovered how a single molecular 'on switch' triggers gene activity that might cause effects ranging from learning and memory capabilities to glucose production in the liver
The effects ranged from learning and memory capabilities to glucose production in the liver.

The 'on switch', a protein called CREB, is a transcription factor - a molecule that binds to a section of DNA near a gene and triggers that gene to make the specific protein for which it codes.

The St Jude team showed that each gene that responds to CREB chooses which co-factors, or helper molecules, CREB uses to activate that gene.

This finding adds an important piece to the puzzle of how cells use CREB to activate specific genes in response to a molecule called cAMP, which acts as a messenger for a variety of stimuli including hormones and nerve signalling molecules called neurotransmitters.

The finding also suggests that the current model scientists use to explain how CREB works is too simple, said Paul Brindle, PhD, associate member of the Department of Biochemistry at St Jude.

Brindle is senior author of a report on this work that appears in the 20 June 2007 issue of The EMBO Journal.

'This more complex view of how CREB works may help us understand how this single transcription factor can stimulate many different genes, depending on which tissues are using it and which signalling molecule caused cAMP to put CREB to work', Brindle said.

A long term implication of this work is that one day it might be possible to manipulate CREB's co-factors to treat disease.

'A drug that blocked the specific co-factors CREB needs in the liver to trigger activity of genes that make glucose could reduce blood levels of this sugar in people with diabetes', Brindle said.

'But at the same time, CREB could continue its other jobs without interruption'.
Other authors of the study include Wu Xu, Lawryn Kasper, Stephanie Lerach and Trushar Jeevan.

This work was supported in part by the National Institutes of Health, a Cancer Center (CORE) support grant and ALSAC.
Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   © 2012
Netgains Logo